Business Context and Reporting Period
This Form 8-K filing by Vivos Therapeutics, Inc. (VVOS) reports a corporate action effective October 25, 2023, with the report dated October 27, 2023. The Company, an emerging growth company incorporated in Delaware, implemented a reverse stock split to maintain its listing on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure adjustments.
Material Changes
- Reverse Stock Split: The Company executed a 1-for-25 reverse stock split of its common stock.
- Share Count Reduction: Issued and outstanding shares were reduced from approximately 29,928,786 to approximately 1,197,151.
- Trading Status: Post-split trading commenced on October 27, 2023, under the symbol "VVOS" with a new CUSIP number (92859E207).
- Equity Adjustments: Outstanding options, warrants, and equity incentive plan shares were proportionately adjusted, including exercise price modifications.
- Fractional Shares: No fractional shares were issued; fractional entitlements were rounded up to the nearest whole share.
Outlook, Risks, and Management Commentary
The primary driver for the reverse stock split was to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2). The action was approved by the Board of Directors under authority granted by stockholders at the 2023 Annual Meeting. The filing does not provide specific forward-looking guidance, risk factors, or commentary on operational outlook beyond the necessity of the split for compliance.
Investor Verification Checklist
- Verify the new CUSIP number (92859E207) for trading and settlement purposes.
- Confirm the adjusted number of shares held in brokerage accounts following the 1-for-25 ratio.
- Review the adjusted exercise prices of any outstanding options or warrants held.
- Monitor the stock price to ensure it remains above the $1.00 minimum bid price requirement.